702 filings
Page 22 of 36
8-K
vtqwht02m
15 Apr 13
Acorda Therapeutics Announces Positive AMPYRA® (dalfampridine) Phase 2 Data in People with Post-Stroke Deficits
12:00am
8-K
wbkyt1i iv
20 Mar 13
Other Events
12:00am
CT ORDER
25ztu5uz
19 Mar 13
Confidential treatment order
12:00am
8-K
8ig7fynv ku4hv
13 Mar 13
Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65th Annual Meeting
12:00am
8-K
4dwh1yl23
7 Mar 13
Other Events
12:00am
S-8
y4qnaez1 kh4
6 Mar 13
Registration of securities for employees
12:00am
8-K
aleq0vz89d r0rh54dy
13 Feb 13
Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am
8-K
hnae9 u0tmxkjoc0lb
7 Feb 13
Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference
12:00am
8-K
765wp
24 Jan 13
Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury
12:00am
8-K
xw0cef478eyoethjxx
7 Jan 13
Results of Operations and Financial Condition
12:00am
8-K
152brg7iozrsg9
21 Dec 12
Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
12:00am
8-K
p4a9m0w60qaq70y
31 Oct 12
Acorda Therapeutics Reports Third Quarter 2012 Financial Results
12:00am
8-K
saeqlp
16 Oct 12
Acorda Therapeutics Announces Hatch-Waxman Extension of AMPYRA® (dalfampridine) Sustained-Release Formulation Patent
12:00am
UPLOAD
ave3ovs1oul
12 Oct 12
Letter from SEC
12:00am
8-K
qaona swx4k2pq
10 Oct 12
Other Events
12:00am
8-K
rhxdhay
9 Oct 12
Acorda Therapeutics Names Jane Wasman President, International
12:00am
CORRESP
te3vsr
13 Sep 12
Correspondence with SEC
12:00am
UPLOAD
hq5mc3trcq
31 Aug 12
Letter from SEC
12:00am